K _i -67/MIB-1 and Recurrence in Pituitary Adenoma

Area of Science:

• Endocrinology
• Oncology
• Pathology

Background:

• Ki-67/MIB-1 is a cellular proliferation marker used in pituitary adenoma assessment.
• Its utility in predicting pituitary adenoma invasiveness is established, but its association with recurrence is variable.
• Understanding the predictive value of Ki-67/MIB-1 for pituitary adenoma recurrence is crucial for patient management.

Purpose of the Study:

• To determine if a high Ki-67/MIB-1 labeling index (LI) predicts recurrence in pituitary adenomas.
• To synthesize institutional data with existing literature for a comprehensive analysis.

Main Methods:

• Retrospective chart review of patients undergoing pituitary adenoma resection with at least one year of follow-up.
• Systematic literature search for studies correlating Ki-67/MIB-1 LI with pituitary adenoma recurrence rates.
• Meta-analysis combining institutional data with eligible published studies.

Main Results:

• Institutional review of 79 patients showed a 26.6% recurrence rate; high Ki-67/MIB-1 LI (>3%) was not directly associated with recurrence in this cohort.
• Systematic review and meta-analysis of 30 articles (including institutional data) involving 18 studies reported a pooled odds ratio (OR) of 4.15 (95% CI: 2.31-7.42) for recurrence in pituitary adenomas with high Ki-67/MIB-1.
• Among studies comparing Ki-67/MIB-1 ≥3% vs. <3%, 6 out of 10 reported statistically significant increased odds of recurrence.

Conclusions:

• A high Ki-67/MIB-1 labeling index is associated with a significantly higher risk of pituitary adenoma recurrence.
• Elevated Ki-67/MIB-1 LI in pituitary adenomas warrants consideration for extended patient follow-up duration.
• This marker can aid in stratifying patients at higher risk for tumor recurrence, informing clinical surveillance strategies.